Von Willebrand Disease
Conditions
Brief summary
The objectives of this study are to evaluate the immediate tolerability and safety of rVWF:rFVIII in subjects with Type 3 Von Willebrand Disease after administration of various dosages of VWF:RCo.
Interventions
BIOLOGICALRecombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII)
Single dose, dose escalation, various cohorts
BIOLOGICALMarketed plasma-derived VWF/FVIII concentrate
Cross-over: recombinant FVIII (rVWF:rFVIII) and marketed plasma-derived VWF/FVIII concentrate
Sponsors
Baxalta now part of Shire
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Subject has voluntarily given written informed consent (before conduct of any study-related procedures) * The subject has hereditary type 3 VWD (\<= 3 IU/dL VWF:Ag)or severe type 1 or type 2A VWD (VWF:RCo \<= 10% and FVIII:C \<20%) * The subject has a medical history of at least 25 exposure days to VWF/FVIII coagulation factor concentrates * The subject has a Karnofsky score \>= 70% * The subject is between 18 to 60 years of age (on the day of signing the informed consent) * NOT APPLICABLE IN ITALY: Female subjects of child-bearing potential must have a negative pregnancy test and agree to practice contraception using a method of proven reliability from the day of screening until the study completion visit * APPLICABLE ONLY IN ITALY: Female subjects of child-bearing potential must have a negative pregnancy test and agree to practice non-hormonal-based contraception using a method of proven reliability (IUD acceptable) from the day of screening until 96 hours after the last investigational drug infusion * NOT APPLICABLE IN ITALY: The subject must agree not to be on any therapy (hormone-based contraception acceptable) interfering with coagulation factor pharmacokinetics until 96 hours after the last investigational drug infusion * APPLICABLE ONLY IN ITALY: The subject must agree not to be on any therapy interfering with coagulation factor pharmacokinetics until 96 hours after the last investigational drug infusion
Exclusion criteria
* The subject has been diagnosed with a hereditary or acquired coagulation disorder other than VWD (including qualitative and quantitative platelet disorders and/or an international normalized ratio (INR) \> 1.4) * The subject has been diagnosed with an ADAMTS13 deficiency with less than 10% ADAMTS13 activity * The subject has a history or presence of VWF inhibitor * The subject has a history or presence of FVIII inhibitor with a titer \>= 0.4 BU (by Nijmegen assay) or \>= 0.6 BU (by Bethesda assay) * The subject has a known hypersensitivity to mouse or hamster proteins * The subject has a medical history of immunological disorders, excluding seasonal allergic rhinitis/conjunctivitis, food allergies or animal allergies * The subject has a medical history of a thromboembolic event * The subject is HIV positive with an absolute CD4 count \< 200/mm3 * The subject has been diagnosed with cardiovascular disease (New York Heart Association (NYHA) classes 1-4) * The subject has been diagnosed with insulin-dependent diabetes mellitus * The subject has an acute illness (e.g. influenza, flu-like syndrome, allergic rhinitis/conjunctivitis) * The subject has been diagnosed with liver disease, as evidenced by, but not limited to, any of the following: serum ALT three times the upper limit of normal, hypoalbuminemia, portal vein hypertension (e.g. presence of otherwise unexplained splenomegaly, history of esophageal varices) * The subject has been diagnosed with renal disease, with a serum creatinine level \>= 2 mg/dL * In the judgment of the investigator, the subject has another clinically significant concomitant disease (e.g. uncontrolled hypertension, diabetes type II) that may pose additional risks for the subject * The subject has been treated with an immunomodulatory drug, excluding topical treatment (e.g. ointments, nasal sprays) within 30 days before enrollment * The subject has been treated with drugs known to induce thrombotic thrombocytopenic purpura (TTP) (e.g. Adenosine diphosphate (ADP) receptor inhibitors (Clopidogrel, Ticlopidine)) within 60 days before enrollment * The subject is receiving or anticipates receiving another investigational and/or interventional drug within 30 days before enrollment * The subject is a lactating female * The subject has a history of drug or alcohol abuse within the last 5 years * The subject has a progressive fatal disease and/or life expectancy of less than 3 months * The subject is identified by the investigator as being unable or unwilling to cooperate with study procedures * The subject suffers from a mental condition rendering him/her unable to understand the nature, scope and possible consequences of the study and/or evidence of an uncooperative attitude * Subject is in prison or compulsory detention by regulatory and/or juridical order
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To demonstrate the immediate tolerability and safety after single-dose injections of rVWF:rFVIII at various doses | Up to 30 days after the last investigational product infusion |
Countries
Austria, Canada, Germany, Italy, United Kingdom, United States
Outcome results
None listed